NEW YORK (360Dx) – Biocrates Life Sciences today announced it is acquiring metabolomics firm Metanomics for an undisclosed amount.
Biocrates, based in Innsbruck Austria, also said that it is closing "a significant financing round to support future growth." It did not provide further details about the funding.
Headquartered in Berlin, Metanomics develops metabolomics biomarkers and provides healthcare services. The acquisition provides Biocrates with complementary skills and technologies, enabling it to serve the metabolomics market as a total solutions provider with a focus on healthcare and pharmaceutical applications, it said.
Biocrates provides metabolomic kits capable of multiplexing up to 400 metabolites across multiple analyte classes in a single run. Metanomics' portfolio includes novel metabolite-based cancer and cardiometabolic clinical biomarkers.
The merged firm "will enable us to provide deep metabolic phenotyping through targeted metabolomics profiling services, customized assays, targeted screening kits, and comprehensive data interpretation," Biocrates CEO Wulf Fischer-Knuppertz said in a statement. He added the merger will allow it to develop kits for diagnostics and companion diagnostics.
Tim Bölke, managing director of Metanomics, will continue to lead the merged firm's Berlin operations and is joining Biocrates as its chief medical officer.
Biocrates' financing round was led by BASF Plant Science, the former owners of Metanomics. Also participating in the round are MIG Fonds and GA Asset Fund. BASF will keep a minority share in Biocrates.